FDA Approves Dupilumab as Add-On for COPD - Medscape
WEB14 hours ago — The US Food and Drug Administration has approved dupilumab as an add-on maintenance therapy for adults whose chronic obstructive pulmonary disease (COPD) is inadequately controlled with inhaler...
Dupixent Approved as Add-On Maintenance Therapy in COPD
WEB9 hours ago — The Food and Drug Administration (FDA) has approved Dupixent (dupilumab) as an add-on maintenance therapy for adults with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype.
FDA approves first monoclonal antibody for COPD - Nature
WEB22 hours ago — The FDA has granted a supplementary approval to Regeneron and Sanofi’s dupilumab (Dupixent) for use as an add-on therapy for inadequately controlled chronic obstructive pulmonary disease (COPD...
Sanofi US News
WEB4 days ago — The US Food and Drug Administration (FDA) has approved Dupixent (dupilumab) as an add-on maintenance treatment of adults with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype.
FDA Approves Dupilumab as First Biologic Treatment for COPD
WEB4 days ago — The FDA approved dupilumab today as the first biologic treatment for patients with uncontrolled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype to significantly help...
FDA Approves Dupixent as First Biologic for COPD Maintenance
WEB4 days ago — On September 27, the US Food and Drug Administration (FDA) approved dupilumab (Dupixent, Sanofi/Regeneron) as an add-on maintenance treatment for adult patients with uncontrolled chronic obstructive pulmonary disease (COPD). Dupilumab is the first biologic medicine approved in the US for COPD.
Dupixent® (dupilumab) Approved in the U.S. as the First-ever
WEB4 days ago — Dupixent is indicated for the approximately 300,000 adults in the U.S. with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype
Dupilumab for COPD with Type 2 Inflammation Indicated by …
WEBMay 21, 2023 — We designed the BOREAS trial to investigate the efficacy and safety of dupilumab in patients with COPD who had evidence of type 2 inflammation despite the receipt of standard inhaled triple ...
Dupilumab for COPD with Blood Eosinophil Evidence of Type 2 ...
WEBJun 27, 2024 — In patients with COPD and type 2 inflammation as indicated by elevated blood eosinophil counts, dupilumab was associated with fewer exacerbations and better lung function than placebo. (Funded by Sanofi and Regeneron Pharmaceuticals; NOTUS ClinicalTrials.gov number, NCT04456673.).
WEBNov 27, 2023 — Dupixent® significantly reduced COPD exacerbations in second positive Phase 3 trial, accelerating FDA submission and confirming potential to become first approved biologic for this serious disease.